NovoCure Limited
NVCR
$17.96
$0.070.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 154.99M | 161.27M | 155.10M | 150.36M | 138.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 154.99M | 161.27M | 155.10M | 150.36M | 138.50M |
| Cost of Revenue | 38.52M | 32.51M | 35.37M | 34.65M | 33.69M |
| Gross Profit | 116.47M | 128.75M | 119.72M | 115.70M | 104.81M |
| SG&A Expenses | 100.56M | 139.89M | 99.93M | 94.35M | 94.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 192.86M | 223.62M | 187.19M | 183.96M | 180.02M |
| Operating Income | -37.87M | -62.35M | -32.09M | -33.61M | -41.52M |
| Income Before Tax | -30.30M | -55.21M | -21.59M | -22.73M | -31.64M |
| Income Tax Expenses | 4.02M | 10.72M | 8.99M | 10.65M | 7.12M |
| Earnings from Continuing Operations | -34.32M | -65.92M | -30.57M | -33.38M | -38.76M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.32M | -65.92M | -30.57M | -33.38M | -38.76M |
| EBIT | -37.87M | -62.35M | -32.09M | -33.61M | -41.52M |
| EBITDA | -34.54M | -60.62M | -29.63M | -30.75M | -38.71M |
| EPS Basic | -0.31 | -0.61 | -0.28 | -0.31 | -0.36 |
| Normalized Basic EPS | -0.17 | -0.47 | -0.12 | -0.14 | -0.18 |
| EPS Diluted | -0.31 | -0.61 | -0.28 | -0.31 | -0.36 |
| Normalized Diluted EPS | -0.17 | -0.47 | -0.12 | -0.14 | -0.18 |
| Average Basic Shares Outstanding | 110.28M | 108.47M | 108.25M | 107.70M | 107.27M |
| Average Diluted Shares Outstanding | 110.28M | 108.47M | 108.25M | 107.70M | 107.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |